-+ 0.00%
-+ 0.00%
-+ 0.00%
Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization
Share
Listen to the news
Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization
  • The European Medicines Agency's CHMP recommended EU marketing authorization for Hansoh Pharmaceutical's aumolertinib on November 12, 2026.
  • The drug, marketed as Aumseqa outside China, is intended to treat non-small cell lung cancer.
  • Marketing authorization remains subject to final European Commission approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261115-12413057), on November 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending